Notice_of_Availability_(CSO)_HT0402-19-S-C001_20190613.pdf

Commercial Solutions Opening

Notice of Availability

HT9402-19-S-C001

Overview of the Funding Opportunity

1. Agency Name

Defense Health Agency (DHA)

2. Issuing Acquisition Office

Defense Health Agency, Managed Care Contracting Division (MC-CD)

3. Funding Opportunity Title

Fiscal Year (FY) 2018 National Defense Authorization Act (NDAA) Section 731 Pilot Program on Health Care Assistance System (FY2018 NDAA 731 Patient Navigator Pilot Program)

4. NAICS Code

524114 Direct Health and Medical Insurance Carriers

5. Announcement Type

Notice of Availability (NoA), Commercial Solutions Opening (CSO) (Deviation DARS: 2018- 00016)

6. Funding Opportunity Number

HT9402-19-S-C001

7. Response Dates

This NoA is open through 26 July 2019, unless announced otherwise. All solutions must be received by 1600 MDT on the closing date to be considered for award.

Additional Overview Information

This NoA sets forth the FY2018 NDAA 731 Patient Navigator Pilot Program requirements, describes the criteria for selecting solutions, their relative importance, and the method of evaluation, as well as instructions for the preparation and submission of solutions.

This NoA is issued under Commercial Solutions Opening authority, which provides for the competitive selection of innovative commercial services. Additional information about Commercial Solutions Openings may be found in Class Deviation 2018-00016, which was authorized under section 879 of the NDAA for Fiscal Year 2017 (Pub. L. 114-328). The award will result in a FAR-covered, commercial Firm-Fixed-Price or Fixed-Price Incentive-Fee contract.

DHA intends to obtain innovative solutions or potential new capabilities that fulfill requirements, close identified capability gaps, or provide potential technology advancements. Innovative is defined as any technology, process or method that is new as of the date of submission of a proposal. It also includes any new application of an existing technology, process, or method.

Solutions submitted in response to this NoA and selected for award are considered to be the result of full and open competition for purposes of 10 U.S.C. chapter 127 and FAR 6.102.

The Defense Health Agency reserves the right to select for award one or none of the solutions submitted in response to this announcement. DHA will not provide funding or reimbursement for costs associated with solution development.

Solutions and price proposals (or any other material) submitted in response to this NoA will not be returned to the applicant. It is the policy of the DHA to treat all submissions as sensitive, competitive information and to disclose their contents only for the purposes of evaluation. An applicant may withdraw a solution at any time before award by written notice or by email sent to the Government point of contact (POC) identified in this NoA.

Funds are not presently available for this acquisition. No contract award will be made until appropriated funds are made available.

Organizational Conflicts of Interest (OCI)

The applicant is hereby notified that DHA has contractual relationships with multiple companies that due to the nature of the performance with DHA, may create an actual or potential organizational conflict of interest, which must be avoided, neutralized or mitigated. It is the responsibility of each applicant to identify if any such actual or potential organizational conflict of interest exist with regard to their solution (see FAR 9.5, Organizational and Consultant Conflicts of Interest).

As a part of the solution, the applicant shall provide the Contracting Officer with information of previous or ongoing work that is in any way associated with this NoA. In the event an actual or potential organizational conflict of interest exists, the applicant shall, in addition to the solution, submit a plan to the Contracting Officer (CO), demonstrating how the applicant will avoid, mitigate or neutralize any actual or potential organizational conflict of interest while supporting this contract and any other DHA contract.

The solution selected to move to Phase 2 must not present an actual or potential organizational conflict of interest, or it must be accompanied by a plan that the CO determines effectively avoids, neutralizes or mitigates a potential or actual organizational conflict of interest.

The above restrictions shall be included in all subcontracts, teaming arrangements and other agreements calling for performance of work which is subject to the organizational conflict of interest restrictions identified in these provisions.

The above provisions may be modified or deleted at the discretion of the Government. The Government reserves the right, in case of a breach, misrepresentation or nondisclosure, to terminate the resultant contract, disqualify the applicant from subsequent related contractual efforts, or pursues any remedy permitted by law, regulation or the terms and conditions of this solicitation.

Applicants shall use their legal name and not a shortened version that could be confused with a parent company or other corporation. Use of an acronym is permissible after the first usage of the full legal name. The applicant shall clearly distinguish information in its solution that it attributes to itself (the applicant) its parent company, affiliate or subsidiary.

Attachments

1. Statement of Objectives (SOO)

2. List of Personally Identifiable Information, Protected Health Information, and Federal

Information Requirements

3. List of potential clauses applicable to a contract awarded as a result of this Notice of

Availability

Solution Submission

The applicant’s solution shall be submitted as an email to patricia.r.legra.civ@mail.mil. The due date and time for the receipt of solutions is 1600 MDT, 26 July 2019. WARNING: PLEASE DO NOT WAIT UNTIL THE LAST MINUTE TO SUBMIT YOUR SOLUTION! The Government will not evaluate late submissions.

Phase 1 Solution File

Each applicant’s solution shall include the following elements:

Cover Page with:

Notice of Availability number (HT9402-19-S-C001) Company name Point of Contact information CAGE Code & DUNS Number Solution Title Screen shot of current SAM.gov registration. It is critical applicants are registered in the System for Award Management (SAM), https://www.sam.gov/, you will not be eligible for an award if not registered in SAM. Additionally, verify you are registered to receive contracts (not just grants) and your address matches between your submittal and

SAM.

When registering in SAM.gov, be sure to select ‘YES’ to the question ‘Do you wish to bid on contracts?’ in order to be able to compete for CSO. If you are only registered to compete for grants, you will be ineligible.

Ensure SAM.gov registration includes completion of FAR and DFARS representations and certifications as well as EFT payment information. (As appropriate, contract-specific certification packages will be provided to the contractor for completion prior to award.)

Type of business, selected among the following categories: “LARGE BUSINESS,”

“SDB,” “OTHER SMALL BUSINESS,” “HBCU,” “MI,” “OTHER EDUCATIONAL,”

OR “OTHER NONPROFIT”

If Joint Venture or teaming arrangement, include a list of partners and the Joint Venture or teaming arrangement agreement as attachment.

Date of solution submission Solution validity period (minimum 180 days) Signature of authorized representative

Solution Element 1 – Draft Performance Work Statement (PWS) must address transition activities, period of performance, proposed reports, incentives, and performance metrics, but need not include a high level of detail;

Solution Element 2 - Proposed value based incentive structure linking payment to performance, cost savings, beneficiary satisfaction, and health outcomes;

Solution Element 3 - Draft price proposal including proposed incentives and how they are to be calculated along with estimated total price and a total maximum price (including all potential incentives and option periods).

Solution Element 4 - Relevant past performance summary to include three references (3 page maximum)

Pitch Day Slide Deck (15 Slide maximum)

OCI Plan, if applicable

Solution documents must use the following format:

Page Size - 8 ½ x 11 inches Margins - 1 inch Spacing - single Font - Times New Roman, 12 point, single-sided pages

Maximum number of pages:

25 pages for Solution Element 1 (draft PWS) 5 pages for Solution Element 2 (value-based incentive structure) No page limit for Solution Element 3 (price proposal) 3 pages for Solution Element 4 (past performance summary and references) 15 slides for Pitch Day slide deck (required, even if live presentation not elected)

Ask Me Anything (AMA)

Due to the large amount of expected interest in this CSO, we will not be answering individual questions through e-mail, except in rare cases at the discretion of the Government. Instead we will be holding a teleconference (AMA) to address all questions in an efficient manner.

The Ask Me Anything teleconference will begin on 10 July, at 1300 MDT/1500 EDT. The AMA will be comprised of: The Commercial Solutions Opening summary, followed by a summary of the 731 Patient Navigator Pilot Program, and finally, questions and answers.

Questions received after this date/time may or may not be answered. DHA will post finalized questions and answers via FBO.gov upon completion.

To access the AMA teleconference, dial in to: 1-866-768-6208 o Enter the Participant Passcode 47769859 followed by #

Nothing said during this teleconference changes the Notice of Availability. If there are any conflicts between what is stated during the teleconference and the written Notice of Availability, the written Notice of Availability takes precedence. Any changes to the Notice of Availability will be made via amendment on FBO.gov

Solution Evaluation

Solutions received by the submission deadline will be evaluated in accordance with the evaluation and selection process listed below. All solutions are treated as procurement sensitive and are disclosed only for the purpose of evaluation. Award will be made to the applicant proposing the best solution to address the objectives outlined in the SOO for a fair and reasonable price and within available funds. A two phase process will be used to select a single applicant for award.

Applicants who submit a solution will receive an invitation to make a live pitch (i.e. oral presentation) of their solution to the DHA team of evaluators during a Pitch Day event to be held on or about the week of 5 August 2019 in San Antonio, TX. A live pitch is not mandatory but is encouraged. All applicants shall submit Pitch Day slides, whether or not the pitch is presented live. Pitch Day details will be provided via e-mail invitation the week following receipt of solutions.

The pitch shall not merely repeat the Statement of Objectives or contain the contents of the PWS pasted into slides, but rather provide convincing evidence the proposed solution will meet the Government’s objectives.

The following examples of convincing evidence are encouraged –

(a) Authentic company URL or web address.

Note: The Government may elect to use the information provided as part of its continuous market research. However, the government is not obligated to use the URL or web address as part of its evaluation process to determine the Selectee or Awardee.

(b) Summary of services currently provided in the open market and how the current solution differs.

(c) Diagrams, graphs, or charts to depict the essence of the proposed solution.

The Government may ask questions/interview applicants during the live pitch. No communication is anticipated with applicants following Pitch Day prior to notification of selection for participation in Phase 2 or exclusion from consideration.

Phase 1 Evaluation

Phase 1 submissions will be evaluated as follows:

ELEMENT 1 - A panel of Subject Matter Experts (SMEs) will assess the draft Performance Work Statement (PWS) and Pitch Day slide deck. The draft in conjunction with the Pitch Day slide deck shall address all objectives in the SOO in a manner that allows the evaluators to fully understand the approach and intended outcomes, but does not require a high degree of detail. The assessment will take place to determine:

SUB-ELEMENT A - Importance to Agency Programs demonstrated through the potential contributions of the solution(s) to improve patient outcomes, patient experience, and reduce costs

SUB-ELEMENT B - The technical merits of the proposed solution

ELEMENT 2 - The proposed value-based incentive structure will be evaluated to determine how effective the proposed incentives will be in motivating the contractor to achieve the pilot objectives.

ELEMENT 3 - Cost/pricing specialists and the Contracting Officer will evaluate the draft price Solution and total price to determine if it is both:

SUB-ELEMENT A - Fair and reasonable

The Government will evaluate applicant’s proposed prices by adding the total price for all incentives and options to the total price for the basic requirement. Evaluation of options does not obligate the Government to exercise the option(s).

Price will not be scored or ranked; price will be evaluated to determine it is fair and reasonable. Price will be evaluated in accordance with DFARS 212.209. Applicants are required to submit other than cost and pricing data to support a fair and reasonable price determination, to include all price information required by the Notice of Availability (NoA). Because price will be evaluated for reasonableness before Phase 2, it is possible an applicant may not be selected because of an unreasonable price. The price submitted in Phase 1 is binding as a ceiling price in Phase 2 and in a subsequent award. Applicants should submit their best price with their original Solution submission.

SUB-ELEMENT B - Within available funds

Each applicant’s total evaluated price, to include all potential incentives and option periods, will be compared to available funds. If the proposed price exceeds available funds it is unawardable and may not be selected for Phase 2.

ELEMENT 4 - The past performance team and/or Contracting Officer will assess the relevant past performance summary, may interview references and may use all other means available to fully vet the past performance history of the applicant. Applicants must have a satisfactory or better past performance record to be considered for Phase 2. This element is pass/fail.

Phase 1 Selection Criteria

With the exception of the pass/fail Past Performance element, elements are listed in order of importance. The solution selection will be based on the individual merits of an applicant’s proposed solution. The applicant whose submittal best satisfies all objectives of the SOO in consideration of the SOO constraints evaluated under the evaluation elements will be selected for negotiation at Phase 2.

Applicants not selected for Phase 2 will be notified of their exclusion from consideration and provided feedback on their submittal, which will contain the basis for exclusion. In the event negotiations with the selected applicant are unsuccessful, the results of the evaluations of the applications received for Phase 1 will be reviewed to select another applicant for negotiations in Phase 2.

Phase 2 Negotiation & Award

The Government will conduct a solution feedback session with the selected applicant after notice of selection. The solution feedback session will address any areas of refinement the Government recommends for the solution approach. The selected applicant will be required to submit the following within 30 days of the session:

ELEMENT 1 - Complete Performance Work Statement (PWS), ELEMENT 2 - Finalized value based incentive structure linking payment to performance, cost savings, beneficiary satisfaction, and improved health outcomes, and

ELEMENT 3 - Final price proposal not to exceed the maximum total price proposed at Phase 1.

All elements are available for negotiation at this juncture. In no circumstance will the maximum price proposed at Phase 1 for Element 3 be exceeded. The Government will present all other terms and conditions including mandatory terms and conditions associated with FAR Part 12 commercial contracts. The selected applicant must be considered a responsible party prior to award IAW FAR 9.104